$1.91
2.55% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US36269B1052
Symbol
GANX
Sector
Industry

Gain Therapeutics Inc Stock price

$1.91
+0.17 9.77% 1M
+0.25 15.06% 6M
-0.25 11.57% YTD
-0.60 23.90% 1Y
-0.85 30.80% 3Y
-9.09 82.64% 5Y
-9.09 82.64% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.05 2.55%
ISIN
US36269B1052
Symbol
GANX
Sector
Industry

Key metrics

Market capitalization $56.46m
Enterprise Value $48.00m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 9.50
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-20.34m
Free Cash Flow (TTM) Free Cash Flow $-19.13m
Cash position $9.07m
EPS (TTM) EPS $-0.89
P/E forward negative
Short interest 1.05%
Show more

Is Gain Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Gain Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Gain Therapeutics Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Gain Therapeutics Inc forecast:

Buy
100%

Financial data from Gain Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.08 0.08
0% 0%
-
-0.08 -0.08
0% 0%
-
- Selling and Administrative Expenses 9.67 9.67
4% 4%
-
- Research and Development Expense 11 11
6% 6%
-
-20 -20
5% 5%
-
- Depreciation and Amortization 0.08 0.08
0% 0%
-
EBIT (Operating Income) EBIT -20 -20
5% 5%
-
Net Profit -21 -21
1% 1%
-

In millions USD.

Don't miss a Thing! We will send you all news about Gain Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gain Therapeutics Inc Stock News

Neutral
GlobeNewsWire
7 days ago
First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected Mid-2025 First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected Mid-2025
Neutral
GlobeNewsWire
9 days ago
GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity
Neutral
GlobeNewsWire
20 days ago
BETHESDA, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present and participate in one-on-one meetings at The Citizens Life Sciences C...
More Gain Therapeutics Inc News

Company Profile

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Head office United States
CEO Gene Mack
Employees 25
Founded 2017
Website www.gaintherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today